AU
UK
CA
NZ
IND
US
Last update at 2026-06-22T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -9.90597M | -7.88000M | -7.63400M | -10.17300M | -12.61500M |
| Minority interest | - | - | - | - | - |
| Net income | -9.90597M | -7.88000M | -7.63400M | -10.23600M | -12.59500M |
| Selling general administrative | 3.66M | 3.05M | 2.96M | 3.14M | 3.85M |
| Selling and marketing expenses | - | - | 0.01M | - | - |
| Gross profit | 0.38M | 0.67M | 0.74M | 0.81M | 0.85M |
| Reconciled depreciation | 0.02M | 0.00700M | 0.01M | 0.01M | 0.01M |
| Ebit | -10.02893M | -8.13000M | -8.19500M | -10.11000M | -12.85600M |
| Ebitda | -10.00474M | -8.12300M | -8.18000M | -10.09600M | -12.84200M |
| Depreciation and amortization | 0.02M | 0.00700M | 0.01M | 0.01M | 0.01M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -10.02893M | -8.13000M | -8.19500M | -10.09600M | -12.84200M |
| Other operating expenses | 10.44M | 8.80M | 8.94M | 10.91M | 13.70M |
| Interest expense | 0.01M | 0.01M | 0.01M | 0.06M | 0.23M |
| Tax provision | - | - | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.28M | 0.29M | 0.51M | 0.22M | 0.02M |
| Net interest income | 0.27M | 0.28M | 0.73M | -0.07700M | 0.00200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | 0.00000M | 0.06M | -0.02000M |
| Total revenue | 0.41M | 0.67M | 0.74M | 0.81M | 0.85M |
| Total operating expenses | 10.41M | 8.80M | 8.94M | 10.91M | 13.70M |
| Cost of revenue | 0.02M | 0.00703M | 0.01M | - | - |
| Total other income expense net | 0.12M | 0.25M | 0.56M | -0.07700M | 0.23M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -9.82800M | -7.88000M | -9.00100M | -10.17300M | -12.61500M |
| Net income applicable to common shares | - | - | - | -10.17300M | -15.20500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 9.51M | 9.12M | 9.99M | 9.28M | 20.25M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.83M | 1.09M | 0.99M | 1.17M | 0.93M |
| Total liab | 3.92M | 3.68M | 3.75M | 4.81M | 5.87M |
| Total stockholder equity | 5.59M | 5.44M | 6.24M | 4.47M | 14.38M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 1.11M | 0.98M | 0.94M | 0.78M | 0.91M |
| Common stock | - | - | - | - | 60.65M |
| Capital stock | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 60.65M |
| Retained earnings | -176.18627M | -166.36100M | -158.48100M | -150.84700M | -140.67400M |
| Other liab | - | - | - | 2.29M | 3.07M |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | 5.53M | 4.83M | 4.28M | 2.98M | 4.39M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2.73M | 2.05M | 2.02M | 2.50M | 2.73M |
| Current deferred revenue | 0.40M | 0.41M | 0.62M | 0.78M | 0.82M |
| Net debt | -5.45692M | -4.72100M | -4.23800M | -2.91600M | -4.26600M |
| Short term debt | 0.06M | 0.05M | 0.03M | 0.05M | 0.05M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.07M | 0.10M | 0.04M | 0.06M | 0.12M |
| Other stockholder equity | 180.65M | 170.67M | 163.60M | 154.19M | 93.28M |
| Property plant equipment | - | - | - | 0.13M | 0.18M |
| Total current assets | 9.44M | 8.98M | 9.91M | 9.16M | 20.07M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 4.47M | 14.38M |
| Short term investments | 3.01M | 3.06M | 4.64M | 5.00M | 14.75M |
| Net receivables | 0.07M | 0.08M | 0.08M | 0.05M | 0.05M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | -0.03900M | -0.04800M |
| Accounts payable | 1.16M | 0.62M | 0.43M | 0.90M | 0.95M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1.13M | 1.13M | 1.13M | 1.13M | 1.13M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.07M | 0.14M | 0.08M | 0.13M | 0.18M |
| Capital lease obligations | 0.07M | 0.10M | 0.04M | 0.06M | 0.12M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00000M | 1.50M | 0.50M | 9.50M | -14.50000M |
| Change to liabilities | - | - | - | -0.86800M | 1.79M |
| Total cashflows from investing activities | -0.00201M | 1.50M | 0.50M | 9.50M | -14.51100M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | 9.72M | 6.71M | 9.14M | 20.46M | 20.46M |
| Change to operating activities | - | - | - | -0.37900M | 0.69M |
| Net income | -9.90597M | -7.88000M | -7.63400M | -10.17300M | -12.61500M |
| Change in cash | 0.70M | 0.55M | 1.30M | -1.41200M | -3.87800M |
| Begin period cash flow | 4.82M | 4.28M | 2.98M | 4.39M | 8.27M |
| End period cash flow | 5.53M | 4.83M | 4.28M | 2.98M | 4.39M |
| Total cash from operating activities | -9.01999M | -7.63700M | -8.44000M | -10.80100M | -9.85800M |
| Issuance of capital stock | 9.64M | 6.71M | 9.14M | 0.00000M | 20.46M |
| Depreciation | 0.02M | 0.00700M | 0.01M | 0.01M | 0.01M |
| Other cashflows from investing activities | - | 1.50M | 0.50M | - | - |
| Dividends paid | - | - | - | -2.59000M | -0.71500M |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | - | - | 0.50M | 23.05M | 0.71M |
| Change to netincome | - | - | - | 0.60M | 0.26M |
| Capital expenditures | 0.00202M | 0.00500M | 0.00200M | 0.00900M | 0.01M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.44M | -0.26700M | -0.94300M | -1.30100M | 2.48M |
| Stock based compensation | 0.34M | 0.36M | 0.26M | 0.26M | 0.40M |
| Other non cash items | 0.43M | 0.14M | -0.13900M | 0.40M | -0.04600M |
| Free cash flow | -9.02201M | -7.64200M | -8.44200M | -10.81000M | -9.86900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CANF Can Fite Biopharma Ltd ADR |
0.06 2.01% | 3.04 | - | 2.97 | 16.92 | 1.15 | 0.92 | 0.10 |
| NVO Novo Nordisk A/S |
2.69 6.23% | 45.88 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.60 3.69% | 45.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
15.16 3.36% | 466.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.56 0.42% | 612.50 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
26 Ben Gurion Street, Ramat Gan, Israel, 5257346
| Name | Title | Year Born |
|---|---|---|
| Dr. Pnina Fishman Ph.D. | Scientific Founder, CEO & Director | 1948 |
| Mr. Motti Farbstein | Chief Operating & Financial Officer | 1964 |
| Dr. Sari Fishman Ph.D. | VP of Bus. Devel. | 1972 |
| Dr. Ilan Cohn Ph.D. | Co-Founder & Chairman | 1954 |
| Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D. | Sr. Clinical Advisor | NA |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer & Executive Chairperson | 1948 |
| Mr. Motti Farbstein | CEO and Chief Financial & Operating Officer | 1964 |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development | 1972 |
| Dr. Ilan Cohn Ph.D. | Co-Founder & Director | 1954 |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board & Consulting Chief Medical Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...